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Abstract
BACKGROUND: The most common cause of female infertility is ovulation disorders, and the most common non-
ovulatory cause is polycystic ovary syndrome (PCOS).
AIM: The aim of the study was to define the reproductive hormone levels in women with infertility due to PCOS, 
depending on the body mass index (BMI).
PATIENTS AND METHODS: The present study involved 100 women aged 25–39 years with infertility due to PCOS 
(PCOS group) and 30 women of the same age with infertility due to tubal-peritoneal causes (control group). Infertility 
due to PCOS was diagnosed according to the Rotterdam criteria. Hormone levels (anti-Müllerian [AMH], follicle-
stimulating [FSH], luteinizing [LH], prolactin, estradiol, and testosterone) in blood serum were determined by ELISA.
RESULTS: We detected a correlation between BMI and sex hormone levels as well as LH/FSH ratio. Notably, the 
ratio of LH/FSH in women with PCOS was significantly different compared to the control group, while at the same 
time, PCOS was significantly more frequent in overweight and obese patients compared to those with normal BMI. 
For instance, the LH/FSH ratio was 30.35% higher in women with Class 2 obesity than in the group of women with 
normal weight. However, in women with both PCOS and Class 3 obesity, the LH/FSH ratio was the lowest among 
those with a BMI of 25.0-39.9.
CONCLUSIONS: We found a hormonal imbalance in women with infertility caused by PCOS: Increased levels 
of AMH and LH, estradiol, and testosterone and decreased FSH levels. Analysis of the relationship between the 
concentration of reproductive hormones and BMI showed a weak inverse relationship between BMI with FSH levels, 
as well as a direct correlation with the levels of LH, prolactin, estradiol, and testosterone, and LH/FSH ratio. Thus, 
obesity exacerbates the hormonal imbalance in women with infertility caused by PCOS.
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Introduction
Infertility is a common disorder that has a 
considerable socioeconomic impact on populations 
while deeply affecting personal health and quality of life 
of individuals [1]. In Ukraine, according to the national 
Ministry of Health 2002–2012 data, 12.5 thousand 
women were diagnosed with infertility each year (122.8 
± 0.33/100,000 women) [2]. Conditions such as ovulatory 
disorders, endometriosis, chromosomal abnormalities, 
fallopian tubal disease, unexplained infertility, and sperm-
related factors can all result in infertility [3], [4]. The 
reproductive system of both men and women can be 
affected by untreated sexually transmitted infections, with 
Chlamydia trachomatis and Neisseria gonorrhoeae being 
the most common STIs resulting in infertility [5], [6].
However, the most common cause of female 
infertility is ovulation disorders, and the most common 
non-ovulatory cause is polycystic ovary syndrome 
(PCOS) [1]. PCOS is a complex hormonal and 
metabolic disorder characterized by oligomenorrhea 
or amenorrhea, hyperandrogenism, and infertility [7]. 
According to Joham et al., the prevalence of PCOS 
varies from 6% to 21%, depending on the diagnostic 
criteria and studied population [8]. Thus, using the 
diagnostic criteria proposed by the National Institute of 
Child Health and Human Development (NICHD, USA) 
and the American National Institute of Health (NIH, 
USA), the prevalence of PCOS is 4–8% among women 
of reproductive age, while according to the Rotterdam 
criteria, about 18% of women have PCOS [9].
The main pathophysiological components 
of PCOS are gonadotropic dysfunction and insulin 
resistance, which are often associated with high body 
mass index (BMI) [10]. Overweight or obesity is diagnosed 
in approximately 60–80% of PCOS patients [11]. Although 
many obese women are fertile, high BMI contributes 
to an increased risk of fertility disorders. Obesity is a 
recognized cause of menstrual and ovulation disorders 
and infertility [12]. Since obesity exacerbates the hormonal 
and clinical features of PCOS and women suffering from 
PCOS have a high risk of obesity [13], we suggest that 
hormonal imbalance resulting in certain body features 
can be linked to the pathogenesis of PCOS.
The aim of the study was to define the 
reproductive hormone levels in women with infertility 
due to PCOS, depending on the BMI.
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Materials and Methods
The study involved 100 women aged 25–39 
years with infertility due to PCOS (PCOS group) and 
30 women of the same age with infertility due to tubal-
peritoneal causes (control group), who were treated at 
“The Clinic of Professor Stefan Khmil” medical center 
from October 2015 to March 2019. The study protocol 
was approved by the Medical Ethics Committees of I. 
Horbachevsky Ternopil National Medical University 
(No. 34-25/10/2019) and the study was conducted in 
accordance with the Helsinki Declaration of 1975, as 
revised in 1983. Informed consent was obtained from 
all patients.
Infertility due to PCOS was diagnosed according 
to the Rotterdam criteria [9]: Menstrual dysfunction 
(presence of oligoovulation, anovulation resulting in 
amenorrhea, oligomenorrhea, and opsomenorrhea) 
or anovulation; clinical and/or biochemical signs of 
hyperandrogenism; and polycystic ovaries confirmed 
by ultrasound. The presence of at least two of the 
three manifestations results in PCOS diagnosis. The 
retrospective analysis group did not include patients 
with adenomyosis, genital endometriosis, and uterine 
fibromyoma (submucous, subserous, or intramural 
types). The cases of tubal-peritoneal infertility were 
diagnosed by laparoscopy or hysterosalpingography.
The height and body weight were measured 
using standard procedures with a stadiometer and 
scales, respectively. WС was measured between the 
ridges of iliac bones and the edge of rib arches at the end 
of exhalation in normal breathing. HC was measured 
at the point of maximum buttocks circumference in a 
horizontal position. BMI was calculated using the formula 
BMI = Body weight (kg)/height (m2). The data were 
interpreted according to the WHO recommendations: 
Normal weight in the range of 18.0–24.9 kg/m2; overweight 
(pre-obesity), 25.0–29.9 kg/m2; Class 1 obesity, 30.0–
34.9 kg/m2; Class 2 obesity, 35.0–39.9 kg/m2; and Class 
3 obesity, >40 kg/m2 [14].
The levels of gonadotropin and sex hormones 
were determined by the laboratory of “The Clinic of 
Professor Stefan Khmil” medical center (accreditation 
number 268604/2019). Basal levels of follicle-
stimulating hormone (FSH) (catalog number EIA-1288), 
luteinizing hormone (LH) (catalog number EIA-
1289), estradiol (catalog number EIA-4399), general 
testosterone (catalog number EIA-1559), anti-Müllerian 
hormone (AMH) (catalog number DSL-10-14400), and 
prolactin (catalog number EIA-1291) were determined 
on days 1–3 and progesterone levels on days 21–22 
of the menstrual cycle. Hormone levels in blood serum 
were determined by ELISA using the “Diagnostic 
Systems Laboratories, Inc.” test systems (USA) and 
“DRG Diagnostics” (Germany).
Statistical analysis of the results was carried 
out using Microsoft Office Excel and Statistica 7.0 
software. Normality of distributions in each of the study 
groups was determined using nomograms, Shapiro–
Wilk, and Lilliefors tests. For the groups with values 
obeying with normal distribution, central tendency 
values were expressed as a mean ± SD. For the groups 
with values not following the normal distribution, central 
tendency was expressed as a median (M), followed 
by lower and upper quartiles (LQ; UQ). To determine 
the impact of each factor on infertility, we constructed 
frequency tables and performed Fisher’s exact test. 
Probability р ˂ 0.05 was considered as significant. The 
analysis of three more normally distributed variables 
was carried out using ANOVA followed by the Tukey’s 
range test for subsequent pairwise comparison of 
groups.
Results
In women with infertility due to PCOS, the 
levels of anti-Müllerian and luteinizing hormones, 
estradiol, and testosterone were elevated compared 
to the control group. At the same time, the 
concentration of FSH was significantly reduced (by 
35.9%) (Table 1). The LH/FSH ratio used in clinical 
practice is used, was significantly higher (1.5 times) 
in the patients with PCOS compared to the control 
group. This indicates a pronounced ovulatory reserve 
and is a risk factor for ovarian hyperstimulation 
syndrome [15].
Table 1: Sex hormone levels and LH/FSH ratio in patients with 
infertility caused by PCOS, M (LQ; UQ)
Hormones Control group PCOS group Mann–Whitney 
confidence interval, р
AMH, nmol/L 2.10 (1.80; 2.30) 6.85 (5.30; 8.70) ˂0.001*
FSH, IU/L (days 2–3 
of MC)
8.70 (8.40; 9.10) 6.40 (6.10; 7.15) ˂0.001*
LH, IU/L (days 2–3 
of MC)
7.25 (7.00; 7.70) 8.35 (7.40; 9,40) ˂0.001*
LH/FSH 0.81 (0.80; 0.90) 1.19 (1.09; 1.36) ˂0.001*
Prolactin, µg/L (days 
2–3 of MC)
13.05 (12.40; 
14.00)
12.50 (10.95; 13.95) ˃0.05
Estradiol, pg/L (days 
2–3 of MC)
27.20 (26.,80; 
28.40)
28.10 (27.30; 32.40) ˂0.05*
Progesterone, ng/L 
(days 21–23 of MC)
14, 15 (13.50; 
15.30)
13.85 (12.80; 15.15) ˃0.05
Testosterone, nmol/L 
(days 2–3 of MC)
1.40 (1.30; 1.80) 3.70 (1.95; 4.75) ˂0.001*
*Statistically significant results. LH: Luteinizing, FSH: Follicle-stimulating, AMH: Anti-Müllerian, PCOS: 
Polycystic ovary syndrome, LQ; UQ: Lower and upper quartiles.
In this study, 42 patients had normal weight 
(95% CI [32.79; 51.80]), and 58 were overweight or 
obese to various classes: 0 (overweight) −24 % (95% 
CI [16.64; 33.29]), Class 1 obesity −16 % (95% CI [9.99; 
24.53]), Class 2 obesity −13 % (95% CI [7.62; 21.12]), 
and Class 3 obesity −5 % (95% CI [1.87; 11.46]). We 
detected a correlation between BMI and sex hormone 
levels (FSH, prolactin, estradiol, and testosterone) as 
well as LH/FSH ratio (Table 2). Notably, the ratio of 
LH/FSH in women with PCOS was significantly different 
compared to the control group, while at the same time, 
PCOS was significantly more frequent in overweight 
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and obese patients compared to those with a BMI in 
the range of 18.5–24.9. For instance, the LH/FSH ratio 
was 30.35% higher in women with Class 2 obesity than 
in the group of women with normal weight. However, in 
women with both PCOS and Class 3 obesity, the LH/
FSH ratio was the lowest among those with a BMI of 
25.0–39.9.
When comparing the level of hormones in 
patients with infertility caused by PCOS to those with 
tubal-peritoneal infertility (control group), the decrease 
in FSH levels was a more important contributor to the 
high than the increase in LH. Similarly, in women with 
a BMI of more than 25.0, the change in LH/FSH ratio 
was mainly driven by the change in FSH (Table 2). 
Thus, the lowest level of FSH was found in women 
with infertility due to PCOS and Class 2 obesity, an 
11.76% decrease compared to the group of women 
with normal weight.
The levels of prolactin in the blood of women 
with infertility caused by PCOS and Classes 1 and 3 
obesity were also significantly higher than in the group 
of women with normal weight. Hyperprolactinemia in 
PCOS is most often associated with increased levels of 
metabolic estrogens. Estradiol levels in the blood serum 
were significantly higher in obese women with infertility 
caused by PCOS compared to women with normal 
weight. Thus, estradiol levels in women with PCOS 
and Class 3 obesity were 28.55% higher compared to 
women with normal body weight and 26.06% compared 
to overweight women (Table 2).
Testosterone levels in women with infertility 
caused by PCOS and with a BMI of more than 
25.0 kg/m2 were significantly higher compared to the 
group of women with normal body weight. However, 
this marker did not demonstrate significant differences 
in women with different degrees of overweight and 
obesity (Table 2).
We studied the relationship between BMI and 
reproductive hormone levels in the patients with PCOS 
caused infertility. BMI had a weak inverse correlation 
with FSH levels (r = −0.28, р ˂ 0.05), as well as direct 
correlation with the LH/FSH ratio (r = 0.40, р ˂  0.05) and 
the levels of LH (r = 0.25, р ˂ 0.05), prolactin (r = 0.32, 
р ˂  0.05), estradiol (r = 0.43, р ˂  0.05), and testosterone 
(r = 0.68, р ˂ 0.05).
Discussion
Since obesity exacerbates the hormonal and 
clinical features of PCOS and women suffering from 
PCOS have a high risk of obesity [13], we analyzed 
the level of hormones relative to BMI in women with 
infertility due to PCOS. In our study, 42% of women with 
infertility caused by PCOS had normal body weight. 
According to Gambineri et al., only 33–50% of women 
with PCOS are overweight or obese, so obesity is not 
the only factor affecting the prevalence or severity of 
PCOS [16]. On the one hand, obese women have a 
higher risk of developing PCOS [17]. At the same time, 
women with PCOS have a higher risk of developing 
obesity [18]. Therefore, it remains unclear whether 
obesity leads to PCOS, or, conversely, PCOS leads to 
obesity.
AMH is a glycoprotein that is synthesized 
by the granular cells of small antral and periantral 
ovarian follicles. Serum AMH levels strongly correlate 
with the number of antral follicles and are more 
strongly associated with ovarian reserve than FSH or 
estradiol [19]. Our findings indicate that serum AMH 
levels in women with PCOS increase, corroborating 
results of other studies [20]. This is probably due to an 
increase in the number of small antral follicles in PCOS. 
Diwailly argues that serum AMH levels are one of the 
main markers of PCOS [21]. Any of the factors that disrupt 
the functioning of granular cells, including obesity, can 
affect the production of AMH [22], [23]. The relationship 
between serum AMH and BMI still remains unclear. 
Some researchers found a weak negative correlation 
between serum AMH concentration and BMI in women 
with PCOS [24], [25], but, after correcting for age, this 
relationship disappeared. Our results are consistent 
with no correlation between AMH and BMI [26], [27]. It is 
worth noting that scientists who found a negligible effect 
of metabolic status on serum AMH levels in PCOS do 
not recommend considering BMI when interpreting AMH 
levels in clinical practice [28]. Changes in serum AMH in 
women with PCOS are mainly associated with impaired 
production of gonadotropins and steroid hormones. We 
found a significant decrease in FSH and an increase in LH 
levels in obese patients with PCOS. There is also a weak 
inverse relationship between BMI and FSH and weak 
direct relationship between BMI and LH levels. These 
Table 2: The levels of reproductive hormones and the LH/FSH ratio depending on BMI in women with infertility due to PCOS (M (LQ; 
UQ)
Groups 1 2 3 4 5
Indicators Normal body weight Overweight Class 1 obesity Class 2 obesity Class 3 obesity
AMH 6.75 (5.40; 8.30) 7.30 (5.80; 10.30) 6.50 (4.95; 8.35) 6.40 (6.10; 10.10) 6.20 (5.00; 6.30)
FSH 6.80 (6.20; 8.00) 6.40 (6.20; 6.90) 6.45 (6.20; 7.10) 6.00 (6.00; 6.10) 6.20 (6.00; 6.30)
LH 7.85 (7.00; 9.10) 8.60 (7.95; 9.45) 8.90 (7.85; 10.85) 9.00 (8.20; 9.70) 8.30 (7.90; 11.70)
LH/FSH 1.12 (1.08; 1.16) 1.27 (1.17; 1.39) 1.27 (1.15; 1.44) 1.46 (1.34; 1.56) 1.08 (1.08; 1.31)
Prolactin 11.55 (7.00; 12.80) 12.75 (12.00; 13.75) 16.30 (12.50; 18.35) 12.40 (12.20; 12.70) 14.50 (14.10; 14.50)
Estradiol 27.85 (26.70; 29.30) 28.40 (27.10; 29.30) 28.95 (28.35; 34.70) 35.60 (28.40; 36.30) 35.80 (34.20; 35.90)
Progesterone (day 21–23 of MC) 13.95 (12.80; 15.20) 13.75 (12.75; 14.20) 13.55 (12.70; 14.70) 14.50 (12.80; 15.30) 15.20 (14.10; 15.20)
Testosterone 1.95 (0.90; 3.00) 4.10 (3.50;4.70) 4.25 (3.65; 6.20) 5.20 (4.30; 6.80) 5.10 (5.00; 7.30)
р˃0.05 for Kruskal–Wallis test for AMH, LH, progesterone (days 21–23 of MC). FSH: р˂0.001 for Kruskal–Wallis test; р˂0.005 (using Bonferroni correction) for pairwise comparisons of groups 1–4, 2–4, 3–4. LH/FSH: р˂0.001 
for Kruskal–Wallis test; р˂0.005 (using Bonferroni correction) for pairwise comparisons of groups 1–2, 1–3, 1–4. Prolactin: р˂0.05 for Kruskal–Wallis test; р˂0.005 (using Bonferroni correction) for pairwise comparisons of 
groups 1–3, 1–5. Estradiol: р˂0.05 for Kruskal–Wallis test; р˂0.005 (using Bonferroni correction) for pairwise comparisons of groups 1–3, 1–4, 1–5, 2–5. Testosterone: р˂0.001 for Kruskal–Wallis test; р˂0.005 (using Bonferroni 
correction) for pairwise comparisons of groups 1–2, 1–3, 1–4, 1–5. LH: Luteinizing, FSH: Follicle-stimulating, AMH: Anti-Müllerian, PCOS: Polycystic ovary syndrome, LQ; UQ: Lower and upper quartiles.
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data can be confirmed by a significantly higher ratio 
of LH/FSH in patients with PCOS. Literature presents 
controversial conclusions on the changes to LH, FSH, 
and LH/FSH ratio in PCOS and obesity. Banaszewska 
et al. did not find significant differences between LH/FSH 
ratio means in the groups of women with and without 
PCOS [29]. Another study found elevated LH/FSH ratio 
in patients with PCOS, notably with no correlation to age 
and BMI [30]. A study by Esmaeilzadeh et al. showed 
that specific age (≥35 years), BMI (≥25 kg/m2), and 
acne were significant indicators of metabolic disorders 
(including obesity) in women with PCOS [31]. Studies 
confirm the relationship between LH, weight, and PCOS: 
Insler et al. reported that in women with PCOS and 
normal body weight, blood serum levels were significantly 
higher compared to patients with obesity, while Yanira 
et al. found an inverse correlation between LH and BMI 
in women with PCOS [32], [33]. A study by Alnakash and 
Al-Tae’e showed an inverse relationship between FSH 
and BMI in obese women with PCOS [34], which our study 
confirms. The pathological secretion of gonadotropin in 
PCOS results in elevated serum LH levels and increased 
LH/FSH ratio [35]. An increase in gonadotropin-releasing 
hormone upregulates transcription of the LH β-subunit 
through the FSH β-subunit, which leads to an increase in 
the LH/FSH ratio in PCOS patients [36].
This study found that in patients with PCOS, 
testosterone levels significantly increase (р ˂ 0.001). At 
the same time, testosterone levels are the lowest in PCOS 
patients with normal body weight compared to overweight/
obesity (р ˂  0.05), and they significantly correlate with the 
type of obesity [37]. Nevertheless, the findings on the 
effect of obesity on the production of androgens in blood 
serum in PCOS are contradictory. Moran et al. report 
that testosterone and androstenedione levels in PCOS 
patients are not connected with BMI [11]. However, 
obesity produces a decrease in sexual hormone-binding 
globulin, increasing free androgens levels [38]. Another 
study indicates that obesity causes an increase in 
testosterone levels in PCOS patients [39], which confirms 
the results of our study. There is a broad agreement that 
women with PCOS experience an increase in visceral 
and subcutaneous fat accumulation caused by an 
increased rate of androgen production [40]. Furthermore, 
Escobar-Morreale et al. suggest that genetic or induced 
excess of testosterone may be the main cause of obesity-
associated with PCOS [41]. On the other hand, Balen 
et al. found the same metabolic disorders in women with 
PCOS and normal body weight as in obese patients [42].
The data on the causative relationship between 
hyperprolactinemia and PCOS remain inconclusive. 
Some authors believe that hyperprolactinemia in PCOS 
is associated with hyperestrogenism and steroidogenesis 
disorders, while others consider hyperprolactinemia 
to be one of the factors that underlie the pathogenesis 
of PCOS [43], [44]. The apparent connection of 
hyperprolactinemia with PCOS can be explained by 
high LH levels in women with PCOS, leading to a 
secondary decrease in dopaminergic tone, causing 
elevated prolactin levels. Another model proposes that 
increased prolactin secretion under PCOS is the effect 
of hyperestrogenemia [45]. Finally, a study by Delcour 
et al., as well as our data, does not show any connection 
between the prolactin levels and PCOS [44]. However, 
there a link between obesity and pathogenesis of 
hyperprolactinemia: In obese women, the spontaneous 
release of prolactin was significantly intensified and 
correlated with the size of visceral adipose tissue [46]. 
Studies also suggest that decreased circulating leptin/
estrogen levels can reduce prolactin levels. Our results 
underscore the correlation between prolactin levels 
and BMI, with significantly higher prolactin levels found 
in women with the android type of obesity. However, it 
remains unclear whether hyperprolactinemia association 
with the weight gain is due to the stimulation of lipogenesis 
or due to dysregulation of the dopaminergic tone of the 
central nervous system [47].
Our study found a small but significant increase 
in serum estradiol levels in PCOS patients. The literature 
on the levels of estradiol in PCOS is inconclusive. 
Anovulation is associated with low estradiol secretion, 
mainly due to peripheral extraglandular conversion 
and minimal progesterone production [48]. Hashemi 
et al. found decreased estradiol levels in PCOS, 
while studies point out to exceedingly high estradiol 
levels [49], [50]. The increase in the level of bioavailable 
estradiol in PCOS can be attributed to reduced sex 
hormone-related globulin levels [51], which are also 
associated with obesity and testosterone levels [38]. 
Estrogens known to normalize body weight and 
glucose homeostasis, preventing obesity [52]. Although 
high levels of estradiol can prevent the development of 
obesity, traditionally, obesity characterized by relative 
hyperestrogenemia [53]. In our study, the level of 
estradiol correlated with BMI. These results suggest 
estradiol-mediated dysregulation of adipose tissue 
formation or a decrease in sensitivity to estradiol.
There are some limitations in our study, the 
most important is relatively small sample size. This 
can affect the significance of some results, and we 
suggest that additional research is needed to confirm 
our findings.
In our study, hormone levels were measured by 
ELISA method. However, liquid chromatography/mass 
spectrometry (LC/MS) is considered a working standard 
for sex steroid assay because of its high sensitivity and 
ability to detect even the lowest concentrations of the 
hormones.
Conclusions
We found a hormonal imbalance in women 
with infertility caused by PCOS: increased levels of 
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anti-Müllerian and luteinizing hormones, estradiol, and 
testosterone and decreased FSH levels. Analysis of the 
relationship between the concentration of reproductive 
hormones and BMI showed a weak inverse relationship 
between BMI with FSH levels, as well as a direct 
correlation with the levels of LH, prolactin, estradiol, 
and testosterone, and LH/FSH ratio. Thus, obesity 
exacerbates the hormonal imbalance in women with 
infertility caused by PCOS.
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